康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02162 康诺亚-B

交易中 09-09 13:59:57

77.000

-2.500

-3.14%

最高79.900	最低76.100	成交量148.99万
今开78.550	昨收79.500	日振幅4.78%
总市值230.23亿	流通市值230.23亿	总股本2.99亿
成交额1.16亿	换手率0.50%	流通股本2.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"康诺亚-B","latestPrice":77,"timestamp":1788933589295,"preClose":79.5,"halted":0,"volume":1489946,"delay":0,"changeRate":-0.031446540880503145,"floatShares":299000000,"shares":299000000,"eps":-1.91,"marketStatus":"交易中","change":-2.5,"latestTime":"09-09 13:59:57","open":78.55,"high":79.9,"low":76.1,"amount":115658192,"amplitude":0.047799,"askPrice":77,"askSize":2000,"bidPrice":76.9,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":3.044545,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788941400000},"marketStatusCode":2,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":79.5,"openAndCloseTimeList":[[1788917400000,1788926400000],[1788930000000,1788940800000]],"volumeRatio":1.788004,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"2665646113","title":"康诺亚-B(02162)：王闽川辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2665646113","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665646113?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:42","pubTimestamp":1788691337,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B(02162)发布公告，王闽川博士已递交辞呈，辞去公司非执行董事职务，自2026年9月4日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02162","BK1161","BK1574","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665364619","title":"康诺亚-B(02162.HK)：王闽川辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2665364619","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665364619?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:42","pubTimestamp":1788691337,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1587","02162","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107689505","title":"康诺亚-B（02162）公布董事会及三大专门委员会组成人员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1107689505","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107689505?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:36","pubTimestamp":1788690990,"startTime":"0","endTime":"0","summary":"2026年9月6日，康诺亚生物医药科技有限公司在港交所发布公告，披露公司董事会最新成员组成及其在审核委员会、薪酬委员会、提名委员会中的职能分工。根据公告，具体安排如下：。公司在公告结尾处确认，本次披露内容自2026年9月6日起生效。公司并未在本公告中披露任何财务数据或经营指标。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126459483","title":"康诺亚-B（02162.HK）：王闽川博士将于2026年9月4日辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1126459483","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126459483?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:31","pubTimestamp":1788690663,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司9月6日公告称，董事会收到王闽川博士的辞呈。王博士将于2026年9月4日起正式辞去公司非执行董事职务。同时，王博士确认，关于其离任并无其他需提请公司股东或香港联合交易所有限公司关注的事项。\\n\\n董事会对王博士在任期内作出的贡献表示感谢，并将于其离任生效后履行相关董事会职责安排。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","IE00B0JY6N72.USD","01951","KURE","09926","LU0315179316.USD","01276","LU0039217434.USD","03329","06160","02269","03759","LU1242518857.USD","HK0000320264.USD","01952","HK0000306685.HKD","02162","LU0327786744.USD","02268","BK1161","BK1589","01530","02596","BK1515","01093","06821","IE00B543WZ88.USD","LU0588546209.SGD","09966","BK1209","SG9999004220.SGD","06990","03692","LU0307460666.USD","02096","LU1251922891.USD","06996","KCE","LU2543165471.USD","LU1880383366.USD","LU0348783233.USD","IE00B5MMRT66.SGD","01177","06078","02273","LU1152091168.USD","LU0856984785.SGD","09996","01548","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664592821","title":"港股异动 | 康诺亚-B(02162.HK)涨超3% 公司国际化战略迎重要里程碑 与Aeira签署独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2664592821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664592821?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:08","pubTimestamp":1788415700,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1583","BK1587","02162","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112572646","title":"康诺亚-B与Aeira签订司普奇拜单抗东南亚及中亚18国独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1112572646","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112572646?lang=zh_cn&edition=full","pubTime":"2026-09-02 21:05","pubTimestamp":1788354349,"startTime":"0","endTime":"0","summary":"2026年9月2日，康诺亚生物医药科技有限公司公告称，公司已与跨国医药公司Aeira Pte. Ltd.签署独家许可协议，涉及自主研发的靶向IL-4Rα单克隆抗体司普奇拜单抗注射液在东南亚、中亚及港澳地区共18个国家和地区的上市注册与商业化。具体金额与比例未在公告中披露。康诺亚将持续负责该产品的生产及供应。康诺亚同时提醒投资者，司普奇拜单抗在上述区域的开发、上市及商业化存在不确定性，投资者买卖公司股票时应审慎行事。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664546816","title":"东方证券股份有限公司(DFZQ)减持康诺亚-B(02162.HK)4.8万股 每股作价78.401港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664546816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664546816?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:19","pubTimestamp":1788347999,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1574","BK1161","BK1587","BK1564","02162","03958","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113968167","title":"康诺亚-B公布2026年8月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1113968167","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113968167?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:58","pubTimestamp":1788339492,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司于2026年9月2日发布2026年8月股份变动月报表，报告期截至2026年8月31日。公告显示，公司本月底法定注册股本为500,000,000股普通股，每股面值为USD 0.0001，合计USD 50,000，与上月底保持一致。在已发行股份方面，截至8月末，康诺亚-B普通股已发行股份数量为298,735,566股，月内无增发、购回或注销活动，库藏股数量保持0股。此外，报告期内并无涉及股份期权计划、可换股票据及其他关联协议的变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856817","title":"汇添富基金管理股份有限公司减持康诺亚-B(02162)4.8万股 每股作价约78.40港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856817","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664856817?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:44","pubTimestamp":1788263089,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，8月27日，汇添富基金管理股份有限公司减持康诺亚-B(02162)4.8万股，每股作价78.4010港元，总金额约为376.32万港元。减持后最新持股数目为1489.2万股，最新持股比例为4.98%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02162","BK1583","BK1161","BK1587","BK1574","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110478434","title":"康诺亚-B：汇添富基金管理股份有限公司减持，好仓比例降至4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110478434","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110478434?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:40","pubTimestamp":1788255636,"startTime":"0","endTime":"0","summary":"汇添富基金管理股份有限公司于2026年8月27日以每股均价78.401港元卖出康诺亚-B股份4.80万股，涉资约376.32万港元。汇添富基金管理股份有限公司此次减持前持有康诺亚-B好仓1494.00万股，占比5.0%；减持后持股量为1489.20万股，好仓比例降至4.98%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887765","title":"大行评级丨里昂：上调康诺亚目标价至104港元，上调今明两年纯利预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887765","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664887765?lang=zh_cn&edition=full","pubTime":"2026-09-01 11:21","pubTimestamp":1788232862,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","BK1583","02162","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662623760","title":"【券商聚焦】国投证券维持康诺亚-B（02162）买入评级 指核心产品放量及BD兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2662623760","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662623760?lang=zh_cn&edition=full","pubTime":"2026-08-26 14:06","pubTimestamp":1787724376,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券发布研报指，康诺亚-B 2026年中期实现营业收入6.17亿元人民币，同比增长24%；实现净利润12.18亿元人民币，上年同期为亏损0.79亿元。收入及利润变化主要受核心产品康悦达销售放量及海外BD里程碑收入确认影响。截至2026年6月30日，公司现金及金融资产合计32.42亿元人民币，较年初增长65%。考虑到康悦达医保放量、海外BD授权持续兑现及CM512等管线临床进展，维持“买入-A”评级，根据DCF模型给予6个月目标价90.37港元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989484","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","BD","02162","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661171632","title":"花旗：康诺亚生物目标价上调至97.5港元 维持“买入/高风险”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2661171632","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661171632?lang=zh_cn&edition=full","pubTime":"2026-08-23 12:47","pubTimestamp":1787460420,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端花旗发布研报称，康诺亚生物（02162）公布2026上半年收入6.17亿元人民币，同比增长24%，其中stapokibart销售额3.93亿元人民币，同比增长132%。管理层将2026全年stapokibart销售指引由7.5亿元人民币上调至8.5亿元人民币，并重申高峰销售目标超过50亿元人民币。该行认为stapokibart、CMG901及CM512的市场潜力尚未完全反映于股价，因此将目标价由85港元上调至97.5港元，维持“买入/高风险”评级。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-23/doc-iniphnkv0667750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661217900","title":"大和：康诺亚-B重申“买入”评级 目标价上调至110港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661217900","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661217900?lang=zh_cn&edition=full","pubTime":"2026-08-23 12:34","pubTimestamp":1787459640,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端大和发布研报称，康诺亚-B（02162） 2026上半年业绩大致符合先前盈利预告及该行估计。管理层将Stapokibart 2026年销售指引上调至8.5亿元人民币。大和重申“买入”评级，目标价由101港元上调至110港元。大和将康诺亚2026年预测每股盈利下调19%，但将2027至2028年预测每股盈利上调65%至128%，因将Ouro收购的里程碑付款由集中于2026年改为分多年确认。同时将2026年预测收入上调6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-23/doc-iniphnky7023213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661265873","title":"大和：上调康诺亚-B(02162.HK)目标价至110港元 重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2661265873","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661265873?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:20","pubTimestamp":1787300448,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1583","02162","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661268762","title":"花旗：上调康诺亚生物(02162)目标价至97.5港元 评级“买入/高风险”","url":"https://stock-news.laohu8.com/highlight/detail?id=2661268762","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661268762?lang=zh_cn&edition=full","pubTime":"2026-08-21 15:49","pubTimestamp":1787298558,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，康诺亚生物(02162)公布2026上半年收入6.17亿元人民币，同比增长24%，其中stapokibart销售额3.93亿元人民币，同比增长132%。管理层将2026全年stapokibart销售指引由7.5亿元人民币上调至8.5亿元人民币，并重申高峰销售目标超过50亿元人民币。该行认为stapokibart、CMG901及CM512的市场潜力尚未完全反映于股价，因此将目标价由85港元上调至97.5港元，维持“买入/高风险”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187110953","title":"异动解读｜康诺亚-B盘中上涨5.14%，科创板上市计划叠加中期业绩扭亏催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1187110953","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187110953?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:35","pubTimestamp":1787279726,"startTime":"0","endTime":"0","summary":"8月21日，康诺亚-B盘中上涨5.14%，报81.75港元，成交额6660.54万港元，延续前一交易日涨势。其中核心产品康悦达销售收入3.93亿元，同比增长132%，受益于医保落地及自建商业化团队快速发力。科创板上市计划有望拓宽公司融资渠道，市场情绪持续发酵。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康诺亚-B异动拉升，科创板上市叠加业绩扭亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660020034","title":"mRNA癌症疫苗实现历史性突破 易方达生物医药ETF(03186)港美股双布局捕捉创新红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2660020034","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660020034?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:45","pubTimestamp":1787215545,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月19日，Moderna与默沙东公布，个人化mRNA癌症疫苗联合Keytruda，在黑色素瘤三期试验期中分析达标。截至2026年8月20日，易方达生物医药ETF  是港交所上市生物医药主题ETF中，唯一同时配置港股及美股生物医药成分的产品。这些成份股的均衡配置，让该ETF能够捕捉医药板块的整体修复行情。本次mRNA癌症疫苗达标，再次说明医疗创新本身就是科技突破，而不只是防御型板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","06990","03186","BK1583","BK1588","09688","159929","BK1161","02162","LU2488822045.USD","BK1587","BK1574","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660703654","title":"港股异动 | 康诺亚-B(02162.HK)涨超5% 公司拟于科创板上市 上半年康悦达®销售同比增长132%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660703654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660703654?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:52","pubTimestamp":1787194369,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1587","BK1583","BK1574","02162"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0579},{"period":"1month","weight":-0.0287},{"period":"3month","weight":0.435},{"period":"6month","weight":0.4681},{"period":"1year","weight":0.0127},{"period":"ytd","weight":0.4874}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0137},{"period":"3month","weight":0.0373},{"period":"6month","weight":-0.0155},{"period":"1year","weight":-0.0124},{"period":"ytd","weight":-0.0122}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康诺亚生物医药科技有限公司是一家生物科技公司，专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法的公司。该公司还专注于医药产品的研究和开发。该公司的主要产品有CM310、CM326、CM313和CM383，可治疗各种成人、青少年及儿童I型免疫性疾病，例如中重度特应性皮炎、中重度哮喘、慢性鼻賨炎伴鼻息肉、过敏性鼻炎，亦可能可以治疗慢性阻塞性肺疾病。该公司还建立了涵盖生物药开发的关键功能的全面一体化平台。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.4,"avgChangeRate":0.01927},{"month":4,"riseRate":1,"avgChangeRate":0.079263},{"month":5,"riseRate":0.2,"avgChangeRate":-0.114444},{"month":6,"riseRate":1,"avgChangeRate":0.128513},{"month":7,"riseRate":0.6,"avgChangeRate":0.112367},{"month":8,"riseRate":0.666667,"avgChangeRate":0.036143},{"month":9,"riseRate":0.833333,"avgChangeRate":0.045663},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"康诺亚-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康诺亚-B,02162,康诺亚-B股票,康诺亚-B股票老虎,康诺亚-B股票老虎国际,康诺亚-B行情,康诺亚-B股票行情,康诺亚-B股价,康诺亚-B股市,康诺亚-B股票价格,康诺亚-B股票交易,康诺亚-B股票购买,康诺亚-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}